Unlocking more answers
EVALUTION® leverages high quality analytical performance from conventional immunodiagnostic approaches with the unique capability to quantify and monitor binding reactions in real-time. This provides the user with novel, timely and hence highly actionable information.
In the spotlight
ZWIJNAARDE (Ghent), Belgium, July 17, 2019. Today, MyCartis and XVIVO Perfusion AB announce a collaboration to engage in the development of a fast diagnostic tool to timely assess the quality of donated organs during ex-vivo perfusion. Such test can guide the transplant surgeon and team on the quality of an organ, the optimal timing of the surgery and the chances of a positive outcome for the recipient.
In a recent whitepaper, MyCartis demonstrated the successful application of interleukin-1β as an indicator for inflammation in lung organs during perfusion. With results generated within 20 minutes, this test meets the required turnaround time for real-time organ assessment as well as organ follow-up. MyCartis and XVIVO decided to expand the testing panel to also enable the quantitation of organ damage next to the degree of inflammation. Both phenomena are negative indicators for successful transplantation. In line with the inflammation test, an assay fit-for-purpose in real-time organ assessment will be developed to measure at least one additional biomarker in the perfusion fluid.
Clinical lab performance with the ease-of-use of a pregnancy test
Interview with Jan-Willem Hoste
What is the most exciting aspect of the Antelope technology?
The possibility to bring clinical grade diagnostics into the hands of families, consumers and first-line healthcare professionals. At the moment, the technology is not there to radically change healthcare systems and provide immediate information on your health. This holds for consumers, nurses or doctors (GP’s). For example, you can’t screen yourself for an STI (sexually transmitted infection), nor can a GP immediately test if you need antibiotics or not. Today, it is necessary to send your sample to a centralized clinical lab. Offering that lab-quality analysis at a factor of 1000 of the price, will allow immediate access (near patient testing). The impact of this on the healthcare system and the reduction of the global cost for the society can potentially be immense.
How do you feel about the match with Mycartis?
After the research period, we raised funding at VLAIO and UGent for a two-year incubation track with the goal of building a system, developing a business proposition and raising additional capital to bring the technology to the market. We did an extensive round of pitching for various VCs and angels and found a great match with Mycartis and its investors. We realized that bringing a medical product to the market requires specific expertise, know-how and facilities. Being able to raise both the necessary funding and source these elements in via Mycartis is a win-win situation. Basically we are able to accelerate and increase our chances to be successful with our developments.
“We believe the Antelope technology will connect the dots: affordable and easy to use, yet without compromising on quality”
MyCartis offers an open platform approach allowing partners to co-develop assays or port existing assay products on the platform. MyCartis also supports an OEM approach (DMAT® technology inside) in which case MyCartis’ technology is integrated in partner’s existing or new instruments.